Core Insights - FMC Corp. shares fell to their lowest level in nearly nine years following disappointing fourth-quarter results and a weak outlook [1][4]. Financial Performance - The company reported fourth-quarter revenue of $1.22 billion, a slight increase from $1.15 billion year-over-year, but below the expected $1.31 billion [2]. - Adjusted profit for the quarter was $224.6 million, or $1.79 per share, exceeding analyst projections of $200.49 million and $1.60 per share [2]. Future Projections - For 2025, FMC projects revenue between $4.15 billion and $4.35 billion, and adjusted EPS between $3.26 and $3.70, indicating minimal improvement from the previous year [3]. Management Commentary - CEO Pierre Brondeau noted that while there was an increase in volume, growth was below expectations as customers reduced inventory levels significantly [4].

Key TakeawaysThe S&P 500 gained 0.4% on Wednesday, Feb. 5, recovering from morning losses as chip giant Nvidia and other AI names reinvigorated the tech sector.Supermicro shares pushed higher after the server maker provided an update on the availability of its latest AI solution.FMC reported a surprise quarterly loss, and shares of the agricultural sciences firm dropped. Major U.S. equities indexes ticked higher on Wednesday, recovering from morning losses as chip giant Nvidia and other AI names reinvigorat ...

When I saw on Wednesday morning that FMC Corp. (NYSE: FMC ) was down 35% from the previous night's close, a popular expression from the world of sports came to mind:I'm Rob Isbitts, founder of Sungarden Investment Publishing. I run the new investing group Sungarden YARP Portfolio, a community dedicated to navigating the modern investment climate with humility, discipline, and a non-traditional approach to income investing. I've been charting investments since the 1980s, and I spent decades an an investment ...

Key TakeawaysFMC Corp. was the biggest decliner in the S&P 500 by a wide margin Wednesday after the release of the company's fourth-quarter results late the day before.FMC reported a surprise net loss for the quarter, while revenue also fell short of estimates.The agricultural sciences company said growth in the fourth quarter was "below our expectations." Shares of FMC Corp. (FMC) skidded more than 30% Wednesday, making the stock by far the biggest decliner in the S&P 500 after reporting a surprise net los ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .In general, I'm very happy with the way things are going. Many parts of my "big picture" thesis are working out according to plan, including the "higher for longer" inflation and interest rate environment.Analyst’s Disclosure: I/we have no stock, option or similar derivative pos ...

FMC (FMC -33.75%) stock crashed 36.3% through 9:50 a.m. ET Wednesday after reporting mixed earnings last night. Heading into the report, analysts forecast that FMC would earn $1.60 per share in Q4, and FMC beat that number with a stick, reporting adjusted profits of $1.79 per share. However, analysts also thought FMC's sales would exceed $1.3 billion. In fact, sales were barely $1.2 billion. FMC Q4 earningsFMC's sales grew 12% organically, but adverse foreign exchange rates limited dollar-denominated sales ...

Core Insights - FMC Corporation reported a loss of 13 cents for Q4 2024, contrasting with earnings of $8.77 in the same quarter last year. Adjusted earnings per share were $1.79, exceeding the Zacks Consensus Estimate of $1.61 [1][2] Revenue Performance - Revenues for Q4 2024 were $1,224.3 million, a 6.8% increase year-over-year, but fell short of the Zacks Consensus Estimate of $1,324.1 million. The revenue growth was driven by a 15% increase in volume, particularly in the United States [2] - North America sales rose 23% year-over-year to $340 million, although this figure missed the Zacks Consensus Estimate of $347.5 million. Latin America sales declined 10% to $390 million, missing the estimate of $516.9 million [3] - In Asia, revenues increased 10% to $307 million, surpassing the Zacks Consensus Estimate of $273.7 million. EMEA saw an 18% increase to $188 million, also beating the estimate of $183 million [4] Full-Year Results - For FY24, FMC reported revenues of $4,246.1 million, a 5.4% decrease from the previous year. Net income was $341.1 million, reflecting a 74.1% decrease, with consolidated earnings per share at $2.72, down 74.2% year-over-year [5] Financial Position - At the end of the quarter, FMC had cash and cash equivalents of $357.3 million, an 18.1% increase year-over-year. Long-term debt stood at $3,027.9 million, a slight increase of 0.1% [6] Guidance - For Q1 2025, revenues are projected to be between $750 million and $800 million, indicating a 16% decrease at the midpoint from Q1 2024. Adjusted EBITDA is estimated to be between $105 million and $125 million, a 28% decrease at the midpoint compared to the prior-year quarter [7] - Full-year 2025 revenues are expected to be in the range of $4.15 billion to $4.35 billion, with adjusted EBITDA estimated between $870 million and $950 million, reflecting a 1% increase at the midpoint from the previous year [8][9] Stock Performance - FMC's stock has gained 1.1% over the past year, compared to a 3% rise in the industry [11]

FMC (FMC) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.61 per share. This compares to earnings of $1.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.18%. A quarter ago, it was expected that this chemical producer would post earnings of $0.49 per share when it actually produced earnings of $0.69, delivering a surprise of 40.82%.Over the last four quarters, the company has ...

Q4 2024 Earnings Presentation February 4, 2025 Q4 2024 Earnings Presentation FMC CORPORATION 1 Safe Harbor Statement Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements made in this presentation are forward- looking statements that are based on our current views and assumptions regarding future events, future business conditions and the outlook for our company based on currently available information. In some cases, you can identify these forward-looking stat ...

Financial Data and Key Metrics Changes - Q4 revenue was $1,220 million, below guidance, but grew 7% year-over-year, with a 9% increase excluding divested sales from the Global Specialty Solutions business [22] - Full year 2024 sales declined 5%, while EBITDA decreased 8%, but EBITDA margin remained stable at 21% [25] - For 2025, full year sales are expected to be between $4,150 million and $4,350 million, flat at the midpoint compared to the prior year, with adjusted EPS projected between $3.26 and $3.70 [27][29] Business Line Data and Key Metrics Changes - Sales from the growth portfolio accounted for over 75% of the revenue growth in Q4, with the plant health business growing 33% [22] - The company anticipates branded sales to continue growing in 2025, but overall sales of Ronaxapyr are expected to decline due to cost-plus contracts and market repositioning [13][14] - The core portfolio is expected to grow at or slightly above market rates, while the growth portfolio is projected to grow significantly above market rates [19][75] Market Data and Key Metrics Changes - The company reported elevated channel inventories in several regions, including Latin America and Asia, impacting sales and pricing strategies [23][24] - The distribution channel in Brazil has undergone consolidation, affecting sales performance and prompting the exploration of new market routes [18] - The market for diamides is expected to grow from $2 billion to an estimated $5 billion over time, with FMC's branded diamides holding a significant market share [51][53] Company Strategy and Development Direction - The company is focusing on a diamide growth strategy, emphasizing the need to lower channel inventory and implement cost reduction measures [9][10] - FMC plans to invest in the sales organization to support new active ingredients and explore new routes to market, particularly in Latin America and EMEA [16][18] - The company aims to achieve substantial growth in 2026 and 2027, driven by new product introductions and a balanced core and growth portfolio [19][75] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the need for aggressive actions to reposition the company and improve market visibility, especially in light of evolving distribution channels [8][9] - The company expects a challenging first quarter in 2025 due to high channel inventories and cautious purchasing behavior from customers [30][31] - Management expressed confidence in the growth potential of new active ingredients and the overall strategy to drive commercialization of innovative products [19][76] Other Important Information - The restructuring program has exceeded savings targets, delivering $165 million in net savings for 2024, with expectations for over $250 million in run rate savings by the end of 2025 [36][41] - Free cash flow for 2024 was $614 million, a significant increase from the previous year, but is expected to decrease to between $200 million and $400 million in 2025 [42][44] - The effective tax rate for adjusted earnings was lower than expected at 10.9% for 2024, with a projected range of 13% to 15% for 2025 [39] Q&A Session All Questions and Answers Question: How does the company expect RenaxaPure to evolve from 2026 and beyond? - Management believes they can compete with generics at current pricing levels and will focus on expanding market reach while also developing high-end formulations to differentiate from generics [79][80][82] Question: Can you clarify the volume guidance for 2025? - Management explained that the increase in volume growth expectations is due to a strategic decision to lower channel inventory, which will drive more sales directly to the market rather than through the channel [85][86]